RBF Capital LLC reduced its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 63.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 54,929 shares of the company's stock after selling 93,522 shares during the quarter. RBF Capital LLC owned 0.07% of Atea Pharmaceuticals worth $183,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the stock. State Street Corp grew its stake in shares of Atea Pharmaceuticals by 0.7% in the 3rd quarter. State Street Corp now owns 1,733,486 shares of the company's stock worth $5,807,000 after buying an additional 11,566 shares in the last quarter. Barclays PLC boosted its stake in shares of Atea Pharmaceuticals by 74.5% during the 3rd quarter. Barclays PLC now owns 177,077 shares of the company's stock worth $593,000 after purchasing an additional 75,624 shares during the period. Virtu Financial LLC purchased a new position in shares of Atea Pharmaceuticals during the 3rd quarter worth about $99,000. JPMorgan Chase & Co. boosted its stake in shares of Atea Pharmaceuticals by 106.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 95,244 shares of the company's stock worth $319,000 after purchasing an additional 49,028 shares during the period. Finally, Peapod Lane Capital LLC bought a new stake in Atea Pharmaceuticals during the 4th quarter valued at about $1,101,000. 86.67% of the stock is owned by hedge funds and other institutional investors.
Atea Pharmaceuticals Trading Up 0.8 %
Shares of AVIR stock traded up $0.03 during trading hours on Tuesday, hitting $2.99. The company's stock had a trading volume of 201,841 shares, compared to its average volume of 292,985. The company has a 50 day moving average of $2.97 and a 200 day moving average of $3.16. The stock has a market cap of $255.29 million, a PE ratio of -1.44 and a beta of 0.17. Atea Pharmaceuticals, Inc. has a 12-month low of $2.60 and a 12-month high of $4.15.
Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). As a group, analysts anticipate that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.
Analyst Ratings Changes
AVIR has been the subject of several recent research reports. Morgan Stanley reduced their price target on shares of Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. William Blair reiterated an "outperform" rating on shares of Atea Pharmaceuticals in a research note on Friday, March 7th.
Read Our Latest Analysis on AVIR
Atea Pharmaceuticals Company Profile
(
Free Report)
Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
See Also
Before you consider Atea Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.
While Atea Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
